• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Define Ventures Appoints Bruce Broussard as Venture Partner

    10/22/24 9:00:00 AM ET
    $EVH
    $HIMS
    $HUM
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care
    Get the next $EVH alert in real time by email

    The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation

    SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companies. 

    Bruce is a seasoned healthcare executive and multi-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Bruce was president and CEO of Humana for over a dozen years. Under his leadership, Bruce led a strategic shift towards expanding the company into an integrated model with a growing care delivery focus. Bruce also held several roles at McKesson Specialty Health including CEO, CFO, President, and Chairman of the Board. He currently serves on the Humana Foundation Board, is Chair of the Board of Directors of the Trust for the National Mall, and is a board member for HP Inc. and One Call.

    "Bruce's extensive background and proven track record in leading healthcare organizations of all sizes makes him uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege to closely partner with Bruce for the past decade, I am confident his decision to join our team will sharpen our investing theses, accelerate our partner companies' growth, strengthen our relationships with large healthcare organizations, and ultimately create a lasting impact on the broader health tech community."

    Bruce is joining a team that pulls the full weight of its network and expertise to play offense and drive results, including securing early customers, shaping commercial strategies, and building high-performing teams. As venture partner, Bruce will leverage his experience driving transformative change within complex healthcare organizations to help Define founders to navigate industry challenges and scale their innovations effectively. His perspective will also strengthen Define's close partnerships with its coalition of large health systems, health plans, employers, and life sciences companies, half of which are customers of Define partner companies.

    "What excites me the most about this role is the opportunity to work with brilliant, innovative entrepreneurs at the earliest stages of their journey," Broussard said. "Being able to see groundbreaking approaches from the start, and having the chance to shape products and help scale and bring them to market is truly invigorating. Ultimately, I chose to work with Define because I believe this firm is uniquely positioned and capable of driving real transformation in healthcare. The strong, trustworthy relationship we've built over the years has shown me that Define's vision aligns perfectly with my own. Together, I believe we can make significant strides in creating a healthcare system that's more efficient, more accessible, and more focused on keeping people healthy."

    Bruce's decision to join Define Ventures stems from his belief that the firm is uniquely positioned and capable of transforming healthcare. He has built a strong and trustworthy relationship with Define over the past several years, including first-hand experience in incubating and spinning out Cohere Health from Humana. This collaborative history underscores the alignment between Bruce's vision for healthcare innovation and Define's strategic approach.

    Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm attracts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE:HIMS) and Unite Us. This announcement follows Frank Williams, co-founder and former CEO of Evolent (NYSE:EVH) joining Define as venture partner earlier this year.

    To learn more about Define Ventures, visit www.definevc.com.

    About Define Ventures

    Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 AUM, we take a high conviction approach in partnering with companies at the earliest stages. We believe the future of healthcare will be defined who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built in this vision, bringing together founders and investors who built category-defining companies and delivered $23 billion in exit value, including Livongo (LVGO), Evolent (NYSE:EVH), and Hims & Hers (NYSE:HIMS).

    Cision View original content:https://www.prnewswire.com/news-releases/define-ventures-appoints-bruce-broussard-as-venture-partner-302282546.html

    SOURCE Define Ventures

    Get the next $EVH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has joined Define Ventures as a venture partner, and what is his background?

      Bruce Broussard, the former CEO of Humana, has joined Define Ventures as a venture partner to drive transformative change in healthcare and support early-stage health tech companies.

    • What is Define Ventures' focus and how much capital do they manage?

      Define Ventures focuses on early-stage health tech companies and has $800 million in assets under management (AUM). They partner with companies typically at the seed, series A, and series B stages.

    • Why has Bruce Broussard chosen to work with Define Ventures?

      Broussard believes Define Ventures is uniquely positioned to drive real transformation in healthcare, based on his strong relationship with the firm and shared vision for healthcare innovation.

    • What role will Bruce Broussard play at Define Ventures?

      Broussard will leverage his extensive experience in healthcare to guide founders through challenges, helping them scale their innovations and strengthen partnerships with large healthcare organizations.

    • Which companies has Define Ventures partnered with, showcasing their investment strategy?

      Define Ventures has partnered with notable companies in the health tech space, including Hims & Hers and Unite Us, highlighting their investment strategy focused on impactful entrepreneurs.

    Recent Analyst Ratings for
    $EVH
    $HIMS
    $HUM

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    6/23/2025Buy → Hold
    Needham
    Hims & Hers Health Inc.
    $HIMS
    6/4/2025$61.00 → $65.00Buy
    Needham
    Humana Inc.
    $HUM
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    Hims & Hers Health Inc.
    $HIMS
    4/29/2025$30.00Buy → Hold
    TD Cowen
    Hims & Hers Health Inc.
    $HIMS
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    Hims & Hers Health Inc.
    $HIMS
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    Evolent Health Inc
    $EVH
    1/10/2025$15.00Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    1/7/2025$35.00Buy
    BTIG Research
    More analyst ratings

    $EVH
    $HIMS
    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 11,581 shares at a strike of $5.01 and sold $556,420 worth of shares (11,581 units at $48.05), increasing direct ownership by 116% to 116,806 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/15/25 4:18:27 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Legal Officer Boughton Soleil sold $132,818 worth of shares (2,572 units at $51.64), decreasing direct ownership by 2% to 153,021 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/12/25 4:33:50 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Dudum Andrew sold $33,384,120 worth of shares (660,000 units at $50.58) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/11/25 5:07:29 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humana and DrFirst Partner on Innovation to Fill Gaps in Care, Improve Outcomes for Patients with Diabetes and Other Chronic Conditions

    Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va., Aug. 13, 2025 /PRNewswire/ -- Humana Inc. (NYSE:HUM), one of the nation's leading health and well-being companies, and health technology pioneer DrFirst today announced the launch of a program designed to close gaps in care for patients with chronic health conditions like diabetes and cardiovascular disease while helping health care providers take timely, informed action. The first phase of this novel program aims to increase the use of statin therapy among eligible patients, aligning with a key quality metric from the Centers for Medicare & Medicaid

    8/13/25 8:04:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/14/25 3:07:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Hims & Hers Health Inc.

    SCHEDULE 13G - Hims & Hers Health, Inc. (0001773751) (Subject)

    8/13/25 12:56:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Evolent Health Inc

    10-Q - Evolent Health, Inc. (0001628908) (Filer)

    8/11/25 6:27:45 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    $HIMS
    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health downgraded by Needham

    Needham downgraded Hims & Hers Health from Buy to Hold

    6/23/25 11:43:05 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously

    6/4/25 7:59:55 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana upgraded by Raymond James with a new price target

    Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00

    5/1/25 7:42:13 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HIMS
    $HUM
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Humana Reports Second Quarter 2025 Financial Results; Raises Full Year 2025 Adjusted EPS and Revenue Guidance

    Reports 2Q25 earnings per share (EPS) of $4.51 on a GAAP basis, Adjusted EPS of $6.27; reports YTD EPS of $14.81 on a GAAP basis, $17.85 on an Adjusted basis 2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the company's previously disclosed expectation of 'approximately 90 percent' Updates FY 2025 GAAP EPS guidance to 'approximately $13.77' from the previous estimate of 'approximately $14.68'; raises Adjusted FY 2025 EPS guidance to 'approximately $17.00', up from the previous 'approximately $16.25' guidance Raises FY 2025 consolidated revenues guidance to 'at least $128 billion' compared to the previous guidance range of $126 billion to $128 billion Affirms

    7/30/25 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $EVH
    $HIMS
    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $EVH
    $HIMS
    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    National Mall of Pickleball Returns for Third Year with Expanded Footprint and New, Central Location

    The National Mall of Pickleball will celebrate America's most accessible sport and the game that serves all in the heart of the National Mall this September The Trust for the National Mall, Humana (NYSE:HUM), and the Humana Foundation announced today that the highly-anticipated National Mall of Pickleball is returning to America's Front Yard, the National Mall, for a third year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625316935/en/ From Friday, September 19 through Sunday, September 21, 2025, the general public can experience a weekend full of pickleball programming, activities, and community with captivating views o

    6/25/25 9:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Launches "Invite" Campaign to Inspire Active Aging Through Pickleball and Community Connection

    Humana Inc. (NYSE:HUM), a leading health and well-being company, is expanding its commitment to senior wellness with the launch of Invite, a new campaign designed to encourage older adults of all fitness levels to stay active, connected and engaged – starting with the fastest-growing sport in America: pickleball. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618737488/en/As part of Humana's new "Invite" campaign, the health and wellness company debuted a television spot featuring senior pickleball athletes extending an open invitation to others to join the fun, stay social, and support their physical and mental well-being. A

    6/18/25 8:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care